Protagonist Therapeutics Inc

For the period ended Dec 31, 2024. Filed Feb 21, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 21, 2025

PTGX$136.26+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(In thousands, except share data)


· · · · · · Accumulated · · · ·
· · · · Additional · · Other · · · · Total
· · Common · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’
· · Stock · Capital · (Loss) Gain · Deficit · Equity
· Shares · Amount · · · · · · · · ·
Balance at December 31, 2021	47,838,330	$—	$709,682	$(299)	$(409,362)	$300,021
Issuance of common stock pursuant to at-the-market offering, net of issuance costs	422,367	—	14,553	—	—	14,553
Issuance of common stock under equity incentive and employee stock purchase plans	686,284	—	4,448	—	—	4,448
Issuance of common stock upon exercise of Exchange Warrants	399,997	—	—	—	—	—
Shares withheld for net settlement of tax withholding upon vesting of restricted stock units	(7,726)	—	(188)	—	—	(188)
Stock-based compensation expense	—	—	24,202	—	—	24,202
Issuance costs related to prior period common stock offering	—	—	25	—	—	25
Other comprehensive income (loss)	—	—	—	(60)	—	(60)
Net income (loss)	—	—	—	—	(127,393)	(127,393)
Balance at December 31, 2022	49,339,252	—	752,722	(359)	(536,755)	215,608
Issuance of common stock pursuant to public offerings, net of issuance costs	5,750,000	—	107,798	—	—	107,798
Issuance of common stock pursuant to at-the-market offering, net of issuance costs	1,749,199	1	24,301	—	—	24,302
Exercise of Warrants in exchange for issuance of Pre-Funded Warrants	—	—	33,813	—	—	33,813
Issuance of common stock upon exercise of Warrants	44,748	—	559	—	—	559
Issuance of common stock under equity incentive and employee stock purchase plans	857,377	—	4,774	—	—	4,774
Shares withheld for net settlement of tax withholding upon vesting of restricted stock units	(31,963)	—	(769)	—	—	(769)
Stock-based compensation expense	—	—	29,293	—	—	29,293
Other comprehensive income (loss)	—	—	—	254	—	254
Net income (loss)	—	—	—	—	(78,955)	(78,955)
Balance at December 31, 2023	57,708,613	1	952,491	(105)	(615,710)	336,677
Issuance of common stock under equity incentive and employee stock purchase plans	2,142,094	—	26,453	—	—	26,453
Issuance of common stock upon exercise of Pre-Funded Warrants	1,205,225	—	—	—	—	—
Shares withheld for net settlement of tax withholding upon vesting of restricted stock units	(20,793)	—	(600)	—	—	(600)
Stock-based compensation expense	—	—	37,554	—	—	37,554
Other comprehensive income (loss)	—	—	—	23	—	23
Net income (loss)	—	—	—	—	275,188	275,188
Balance at December 31, 2024	61,035,139	$1	$1,015,898	$(82)	$(340,522)	$675,295

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.